

SUPPLEMENTARY FIG. 1. The convergence graph of the tocolytic agents on the success rate of external cephalic version.



SUPPLEMENTARY FIG. 2. The trace plot of the tocolytic agents on the success rate of external cephalic version.



SUPPLEMENTARY FIG. 3. The convergence graph of the tocolytic agents on vaginal delivery of external cephalic version.



SUPPLEMENTARY FIG. 4. The trace plot of the tocolytic agents on vaginal delivery of external cephalic version.



SUPPLEMENTARY FIG. 5. Heterogeneity test results of the tocolytic agents on the success rate of external cephalic version.
CrI, credible interval; NA, not applicable.



SUPPLEMENTARY FIG. 6. Heterogeneity test results of the tocolytic agents on vaginal delivery of external cephalic version.
CrI, credible interval.



SUPPLEMENTARY FIG. 7. Heterogeneity test results of the tocolytic agents according to different administration on the success rate of external cephalic version.

iv, intravenously; sc, subcutaneously; po, peros; CrI, credible interval.



SUPPLEMENTARY FIG. 8. Heterogeneity test results of the tocolytic agents according to different administration on vaginal delivery rate of external cephalic version.

iv, intravenously; sc, subcutaneously; po, peros; CrI, credible interval.



SUPPLEMENTARY FIG. 9. Heterogeneity test results of the tocolytic agents on the incidence of common adverse effects.
CrI, credible interval.



SUPPLEMENTARY FIG. 10. Heterogeneity test results of the tocolytic agents on the incidence of abnormal fetal heart rate.



SUPPLEMENTARY FIG. 11. Node-splitting results of the tocolytic agents on the success rate of external cephalic version.
CrI, credible interval.



SUPPLEMENTARY FIG. 12. Node-splitting results of tocolytic agents on vaginal delivery rate of external cephalic version.
CrI, credible interval.



SUPPLEMENTARY FIG. 13. Node-splitting results of tocolytic agents according to different administration success rate of external cephalic version.
iv, intravenously; sc, subcutaneously; po, peros; CrI, credible interval.



SUPPLEMENTARY FIG. 14. Node-splitting results of tocolytic agents according to different administration on vaginal delivery rate of external cephalic version.
iv, intravenously; sc, subcutaneously; po, peros; CrI, credible interval.



SUPPLEMENTARY FIG. 15. Node-splitting results of tocolytic agents on the incidence of common adverse effects.
CrI, credible interval.



SUPPLEMENTARY FIG. 16. Node-splitting results of tocolytic agents on the incidence of abnormal fetal heart rate.
CrI, credible interval.

SUPPLEMENTARY TABLE 1. Convergence Results of the Applied Tocolytic Agents on the Success Rate and Vaginal Deliver Rate of ECV.

	ECV success rate		Vaginal delivery rate	
	Point est.	Upper C.I.	Point est.	Upper C.I.
d.atosiban.fenoterol	1.00016638676128	1.00019432655083	1.00041369087172	1.00063500896877
d.nitroglycerin.terbutaline	1.0006783537997	1.00206607785082	1.00047768774574	1.00127076838001
d.placebo.nifedipine	1.00023592327695	1.00062162393743	1.00047708245344	1.00082186220956
d.ritodrine.atosiban	1.00030911043797	1.00058059053528	1.000312686	1.00049650777213
d.ritodrine.nitroglycerin	1.00028851526008	1.00080907429543	1.00051024114508	1.00087649172567
d.ritodrine.placebo	1.00068299429942	1.00184699536128	1.00094719533319	1.00219548605455
sd.d	1.00085468370544	1.00235999749201	1.00378134924377	1.01108934087374

ECV, external cephalic version.